DK2440239T3 - Hæmoglobinsammensætninger - Google Patents

Hæmoglobinsammensætninger Download PDF

Info

Publication number
DK2440239T3
DK2440239T3 DK10727289.0T DK10727289T DK2440239T3 DK 2440239 T3 DK2440239 T3 DK 2440239T3 DK 10727289 T DK10727289 T DK 10727289T DK 2440239 T3 DK2440239 T3 DK 2440239T3
Authority
DK
Denmark
Prior art keywords
hemoglobin
oxygen
peg
composition
blood
Prior art date
Application number
DK10727289.0T
Other languages
English (en)
Inventor
Abraham Abuchowski
Steven Sloshberg
Keith O'hare
Original Assignee
Prolong Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42779888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2440239(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prolong Pharmaceuticals Llc filed Critical Prolong Pharmaceuticals Llc
Application granted granted Critical
Publication of DK2440239T3 publication Critical patent/DK2440239T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (17)

1. Sammensætning, der omfatter et kovalent konjugat mellem et funktionelt, nativt hæmoglobinmolekyle og mindst ét molekyle af poly(ethylenglycol), hvilken sammensætning omfatter: a. en vandopløselig hæmoglobinfraktion, der omfatter en gruppe af hæmoglobinmolekyler, hvor hvert element af gruppen af hæmoglobinmolekyler; i. er kovalent konjugeret til mindst ét molekyle af poly(ethylenglycolet) via en amindel af en aminosyrerest (f.eks. en ε-amindel af en lysinrest); ii. er fri for kemiske tværbindingsmidler; og iii. har et P50 på fra 9 mm Hg til 14 mm Hg; og b. en vandopløselig stabiliseringsfraktion, der gør gruppen af hæmoglobinmolekyler oxideringsresistent, hvilken fraktion omfatter et stabiliseringsmiddel, der omfatter et strukturelement, der er mere reaktivt med oxygen end gruppen af hæmoglobinmolekyler; og c. en fortynderfraktion, der omfatter en farmaceutisk acceptabel fortynder, hvori hæmoglobinfraktionen kan opløses, hvor sammensætningen er fri for virusaktivitet og stabilt omfatter mindre end 5 % methæmoglobin; hvor sammensætningen fremstillet ved hjælp af en fremgangsmåde omfatter: i. udsættelse af en opløsning af deoxideret hæmoglobin og et stabiliseringsmiddel for en termisk virusinaktiveringsproces, der omfatter eksponering af opløsningen for cn temperatur, der er tilstrækkeligt høj til at inaktivere enhver virusaktivitet i opløsningen (f.eks. 60 °C), hvor eksponeringen sker i et tidsrum, der er tilstrækkeligt til at opnå inaktiveringen af enhver virusaktivitet i opløsningen (f.eks. 10 timer), hvor stabiliseringsmidlet omfatter et strukturelement, der er mere reaktivt med oxygen end det deoxiderede hæmoglobin i opløsningen, hvorved oxygenbinding ved det deoxiderede hæmoglobin minimeres, hvor opløsningen omfatter en mængde af stabiliseringsmidlet, der er tilstrækkelig til at forebygge dannelse af mere end 5 % methæmoglobin i den termiske virusdeaktiveringsproces; og derefter reoxidering af det deoxiderede hæmoglobin for at danne en reoxideret viralt inaktiveret hæmoglobinopløsning; og ii. etablering af kontakt mellem den reoxiderede viralt inaktiverede hæmoglobinopløsning fra trin (i) med et aktiveret poly(ethylenglycol)molekyle med en reaktivitet, der er komplementært til en aminosyrerest af hæmoglobinet, hvorved der dannes et kovalent konjugat mellem poly(ethylenglycol) og hæmoglobinmolekyler i opløsningen.
2. Sammensætning ifølge krav 1, hvor hvert element af gruppen af hæmoglobinmolekyler er kovalent konjugeret til fem eller flere af poly(ethylenglycol)-delen via amindelen af fem eller flere af aminosyresten.
3. Sammensætning ifølge et hvilket som helst foregående krav, hvor hæmoglobinmolekylet er bundet til et element udvalgt blandt oxygen og carbonmonoxid.
4. Sammensætning ifølge krav 3, hvor hæmoglobinmolekylet er i stand til at overføre et element udvalgt blandt det bundne oxygen og det bundne carbonmonoxid til et væv, som hæmoglobinet er i kontakt med.
5. Sammensætning ifølge krav 1, fremstillet ved hjælp af fremgangsmåden, der endvidere omfatter én eller flere af: (iii), før trin (i), deoxidering af en opløsning af oxideret hæmoglobin, hvorved opløsningen af det deoxiderede hæmoglobin dannes; og (iv), før trin (i), dannelse af opløsningen af det deoxiderede hæmoglobin med stabiliseringsmidlet.
6. Sammensætning ifølge krav 5, hvor deoxideringen frembringer et deoxideret hæmoglobinmolckylc, der hverken er (i) bundet til oxygen eller carbonmonoxid; eller (ii) er bundet til carbonmonoxid.
7. Sammensætning ifølge krav 5, hvor hæmoglobinmolekylet er bundet til et element udvalgt blandt oxygen og carbonmonoxid.
8. Sammensætning ifølge krav 7, hvor hæmoglobinmolekylet er i stand til at overføre et element udvalgt blandt det bundne oxygen og det bundne carbonmonoxid til et væv.
9. Sammensætning ifølge krav 1, hvor hæmoglobinet er bundet til CO.
10. Sammensætning ifølge krav 1, hvor hæmoglobinet ikke er bundet til CO.
11. Sammensætning ifølge kravene 9 og 10, hvor a. når hæmoglobinet er bundet til CO, fortynderffaktionen omfatter en phosphatbufferet saltopløsning; og b. når hæmoglobinet ikke er bundet til CO, fortynderfraktionen omfatter en hypertonisk saltopløsningsfortynder.
12. Sammensætning ifølge krav 11, hvor den hypertoniske saltopløsningsfortynder indbefatter NaCl ved en koncentration på fra 3 % til 7 %.
13. Sammensætning ifølge et hvilket som helst af kravene 1 til 12 til anvendelse i: (i) indgivelse af oxygen eller carbonmonoxid til væv; (ii) behandling af: traume, hæmoragisk chok, iskæmi, reperfusionsskade eller seglcelleanæmi i hvert tilfælde under opretholdt dilation af kollaterale arterier; (iii) induktion af angiogenese eller øgning af blodstrømning til væv; (iv) behandling eller forebyggelse af hypoxi som følge af blodtab, anæmi, shock, myokardieinfarkt, apopleksi eller traumatisk hjernelæsion; eller (v) hyperoxidering af tumorer for at forbedre den terapeutiske effekt af strålingsterapi eller kemoterapi.
14. Sammensætning ifølge krav 1, fremstillet ved hjælp af fremgangsmåden, hvor temperaturen er ca. 60 °C.
15. Sammensætning ifølge krav 1, fremstillet ved hjælp af fremgangsmåden, hvor tiden er fra ca. 1 til ca. 12 timer.
16. Sammensætning ifølge krav 1, fremstillet ved hjælp af fremgangsmåden, hvor stabiliseringsmidlet er en aminosyre.
17. Sammensætning ifølge krav 16, hvor stabiliseringsmidlet er cystein.
DK10727289.0T 2009-06-09 2010-06-09 Hæmoglobinsammensætninger DK2440239T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18554709P 2009-06-09 2009-06-09
PCT/US2010/038046 WO2010144629A1 (en) 2009-06-09 2010-06-09 Hemoglobin compositions

Publications (1)

Publication Number Publication Date
DK2440239T3 true DK2440239T3 (da) 2017-10-16

Family

ID=42779888

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17188857.1T DK3266463T3 (da) 2009-06-09 2010-06-09 Hæmoglobinsammensætninger
DK10727289.0T DK2440239T3 (da) 2009-06-09 2010-06-09 Hæmoglobinsammensætninger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17188857.1T DK3266463T3 (da) 2009-06-09 2010-06-09 Hæmoglobinsammensætninger

Country Status (31)

Country Link
US (3) US10080782B2 (da)
EP (2) EP2440239B1 (da)
JP (3) JP6227870B2 (da)
KR (4) KR102170375B1 (da)
CN (1) CN102458451B (da)
AR (1) AR077041A1 (da)
AU (4) AU2010258752B2 (da)
BR (1) BRPI1010775A2 (da)
CA (1) CA2764872C (da)
CL (1) CL2011003091A1 (da)
CY (1) CY1119578T1 (da)
DK (2) DK3266463T3 (da)
ES (2) ES2643462T3 (da)
HR (1) HRP20171480T1 (da)
HU (1) HUE037163T2 (da)
IL (1) IL216404A (da)
LT (1) LT2440239T (da)
ME (1) ME02979B (da)
MX (1) MX342787B (da)
MY (3) MY192541A (da)
NO (1) NO2440239T3 (da)
NZ (1) NZ597022A (da)
PL (2) PL2440239T3 (da)
PT (1) PT2440239T (da)
RS (1) RS56496B1 (da)
RU (1) RU2589254C2 (da)
SI (1) SI2440239T1 (da)
SM (1) SMT201700546T1 (da)
TW (1) TWI626057B (da)
WO (1) WO2010144629A1 (da)
ZA (1) ZA201109176B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102170375B1 (ko) 2009-06-09 2020-10-27 프로롱 파마슈티컬스, 엘엘씨 헤모글로빈 조성물
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US8609815B2 (en) * 2010-09-02 2013-12-17 Sangart, Inc. Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
CN109925318A (zh) 2011-01-14 2019-06-25 洛杉矶儿童医院 用于治疗包括镰状细胞疾病的疾病的一氧化碳溶液
ES2432075T3 (es) * 2011-07-23 2013-11-29 Sastomed Gmbh Espray para heridas
CN104159591A (zh) 2011-11-07 2014-11-19 通用医疗公司 红细胞的处理
US10729748B2 (en) * 2012-01-13 2020-08-04 Mölnlycke Health Care Ab Scarring reducing wound treatment
EP2827887A4 (en) 2012-03-20 2016-04-20 Einstein Coll Med METHOD FOR IMPROVING THE EFFECTIVENESS OF BLOOD TRANSFUSIONS
CN104411807B (zh) 2012-04-03 2018-10-02 桑加特公司 琥珀酰亚胺活化型硝酰化合物及其用于蛋白质硝酰化的使用方法
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
CN105188761B (zh) * 2013-03-15 2020-05-15 桑加特公司 聚环氧烷戊酸酯血红蛋白缀合物
WO2014205077A1 (en) * 2013-06-21 2014-12-24 Prolong Pharmaceuticals, LLC Hemoglobin compositions
CN103387613B (zh) * 2013-08-02 2016-12-28 西北大学 一种血红蛋白及血红蛋白氧载体病毒灭活的方法
CN103690978B (zh) * 2013-12-19 2017-01-25 陕西佰美基因股份有限公司 一种用于血红蛋白及血红蛋白氧载体灭活病毒的方法
WO2016077825A1 (en) * 2014-11-14 2016-05-19 Aima Biotech Conjugated proteins
CN105749257B (zh) * 2016-01-25 2019-12-06 四川大学华西医院 一种血红蛋白类携氧纳米凝胶及其制备方法和用途
CN107007625A (zh) * 2016-01-27 2017-08-04 上海本素医药科技有限公司 含一氧化碳的血液制剂及其在制备抗炎症药物中的应用
US10973883B2 (en) * 2016-05-19 2021-04-13 University of Pittsburgh—of the Commonwealth System of Higher Education Reduced oxygen carriers and their use for the treatment of carboxyhemoglobinemia
US10662063B1 (en) * 2016-06-06 2020-05-26 University Of Puerto Rico Photosensitized release of nitric oxide
CN107625954A (zh) * 2016-07-19 2018-01-26 上海本素医药科技有限公司 含一氧化碳的血红蛋白制剂及其在抗炎症中的应用
JP7837502B2 (ja) * 2017-05-19 2026-03-31 ヘマネクスト インコーポレイテッド 外傷の方法および治療
CN107952072B (zh) * 2017-11-28 2021-07-20 深圳先进技术研究院 载药载氧杂交蛋白纳米粒的制备方法、载药载氧杂交蛋白纳米粒和应用
CN111936059B (zh) * 2018-03-27 2024-09-06 精密科学公司 稳定血红蛋白的方法和实施该方法的试剂
US20210352887A1 (en) * 2018-10-12 2021-11-18 VirTech Bio, Inc. Oxygenation media for ex-vivo preservation of organs and tissues
WO2021034416A2 (en) 2019-07-02 2021-02-25 Hbo2 Therapeutics, Llc Hemoglobin substitute mixtures including reconstituted plasma and platelets and their manufacture and use
BR112022021291A2 (pt) * 2020-04-23 2022-12-06 Kalocyte Inc Composições de veículos de oxigênio de automontagem
JP2023531508A (ja) * 2020-06-23 2023-07-24 ヴィルテック バイオ，インク． 出血性ショックを処置するための組成物および方法
US20230398141A1 (en) * 2020-09-08 2023-12-14 The Brigham And Women's Hospital, Inc. Therapeutic carbon monoxide formulations
WO2022184005A1 (en) 2021-03-01 2022-09-09 Billion King International Limited Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof
CN113813372B (zh) * 2021-09-26 2025-01-21 云锦华彰(北京)生物科技有限公司 血红素组合物、药物组合物及其应用
US20250064724A1 (en) * 2021-11-18 2025-02-27 Virginia Commonwealth University Modular field-stable bio-artificial blood substitute
CN113975378A (zh) * 2021-11-19 2022-01-28 润方（北京）生物医药研究院有限公司 一种聚合血红蛋白在制备治疗缺血性脑卒中药物的应用
US20250326819A1 (en) * 2022-10-14 2025-10-23 Prolong Pharmaceuticals, LLC A stable hemoglobin protein composition
WO2025222053A1 (en) * 2024-04-17 2025-10-23 Prolong Pharmaceuticals Llc Improved dosing regimen of pegylated hemoglobin
WO2025222059A1 (en) * 2024-04-17 2025-10-23 Prolong Pharmaceuticals Llc Method of treating cancer using pegylated bovine hemoglobin
CN119700997A (zh) * 2025-02-27 2025-03-28 中国人民解放军军事科学院军事医学研究院 聚乙二醇牛血红蛋白偶联物的应用

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991181A (en) 1975-06-18 1976-11-09 Warner-Lambert Company Injectable stroma free hemoglobin solution and its method of manufacture
US4401652A (en) 1980-12-31 1983-08-30 Allied Corporation Process for the preparation of stroma-free hemoglobin solutions
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
DE3481109D1 (de) 1983-05-09 1990-03-01 Novo Nordisk As Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren.
US5281579A (en) * 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
US4831012A (en) * 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
US5084558A (en) 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
GB8710598D0 (en) 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
US5428061A (en) 1988-09-15 1995-06-27 Schwarz Pharma Ag Organic nitrates and method for their preparation
US5558985A (en) 1989-03-27 1996-09-24 Bionostics Incorporated Stable hemoglobin reference solution
EP0470128B2 (en) 1989-04-19 2003-08-13 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5342940A (en) 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
US5284872A (en) 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5386014A (en) 1989-11-22 1995-01-31 Enzon, Inc. Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute
US5478806A (en) 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5234903A (en) 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
JP3330932B2 (ja) 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
EP1479395A1 (en) 1991-02-28 2004-11-24 Novo Nordisk A/S Modified factor VII
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5376524A (en) 1991-04-01 1994-12-27 Thomas Jefferson University Platelet storage medium containing acetate and phosphate
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
AU3071592A (en) 1991-11-14 1993-06-15 Brigham And Women's Hospital Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
WO1993022336A1 (en) 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
US5264555A (en) 1992-07-14 1993-11-23 Enzon, Inc. Process for hemoglobin extraction and purification
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5650447A (en) 1992-08-24 1997-07-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitric oxide-releasing polymers to treat restenosis and related disorders
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
DE4321306A1 (de) 1993-06-26 1995-01-05 Sanol Arznei Schwarz Gmbh Disulfide
US5407579A (en) 1993-07-02 1995-04-18 National Science Council Hemoglobin purification
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5691452A (en) 1995-03-23 1997-11-25 Biopure Corporation Method for preserving a hemoglobin blood substitute
US6271351B1 (en) 1995-03-23 2001-08-07 Biopure Corporation Method for preserving a hemoglobin blood substitute
US5585484A (en) 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5932538A (en) 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US5807847A (en) 1996-06-04 1998-09-15 Queen's University At Kingston Nitrate esters
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5833973A (en) 1996-06-28 1998-11-10 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Crosslinked elastomeric silicones in aqueous emulsion cosmetic compositions
US5808011A (en) 1996-07-01 1998-09-15 Biopure Corporation Method for chromatographic removal of prions
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
WO1998019672A1 (en) 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
AU735799C (en) 1997-02-28 2005-04-28 Regents Of The University Of California, The Methods and compositions for optimisation of oxygen transport by cell-free systems
JP4856295B2 (ja) 1997-07-03 2012-01-18 アメリカ合衆国政府 新規な一酸化窒素放出アミジン誘導ジアゼニウムジオレート及びその組成物
ZA988662B (en) * 1997-10-10 1999-03-31 Baxter Int Storage-stable hemoglobin compositions
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP3786832B2 (ja) 1998-01-07 2006-06-14 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 分解性のヘテロ二官能性ポリ（エチレングリコール）アクリレート及びそれから誘導されるゲル及び複合体
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
DE19838481C1 (de) 1998-08-25 2000-03-23 Michael T Witt Anlage zur solarthermischen Energiegewinnung
US6773613B1 (en) 1998-10-15 2004-08-10 Sangart, Inc. Method for production of stroma-free hemoglobin
ATE408020T1 (de) 1998-11-06 2008-09-15 Novo Nordisk Healthcare Ag Verfahren zur herstellung von faktor vii
US6437102B1 (en) 1999-11-24 2002-08-20 Bayer Corporation Method of separating prions from biological materials
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
DK1259563T4 (da) 1999-12-22 2016-11-21 Nektar Therapeutics Fremgangsmåde til fremstilling af 1-benzotriazolylcarbonat-estre af vandopløselige polymerer
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
DE60143292D1 (de) 2000-05-03 2010-12-02 Novo Nordisk Healthcare Ag Varianten des menschlichen Koagulationsfaktors VII
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
AU8755001A (en) 2000-09-13 2002-03-26 Novo Nordisk As Human coagulation factor vii variants
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
WO2003013432A2 (en) 2001-08-10 2003-02-20 Nitromed, Inc. Methods of use for novel sulfur containing organic nitrate compounds
US6649072B2 (en) 2001-11-16 2003-11-18 Robert Brandt Method for producing autologous platelet-rich plasma
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US7001715B2 (en) 2002-02-28 2006-02-21 Biopure Corporation Purification of red blood cells by separation and diafiltration
DE10212321A1 (de) 2002-03-20 2003-10-09 Sanguibio Tech Ag Verwendung eines oder mehrerer von Plasma und Zellwandbestandteilen befreiten natürlichen oder modifizierten Sauerstoffbinder zur externen Behandlung offener, insbesondere chronischer Wunden
US7144989B2 (en) 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
US6901941B2 (en) * 2002-07-10 2005-06-07 Air Products And Chemicals, Inc. Vessel with optimized purge gas flow and method using same
US20040072729A1 (en) * 2002-10-10 2004-04-15 Sunbio Inc. High oxygen affinity PEG-hemoglobin as treatment for brain stroke
JP4699028B2 (ja) 2002-11-08 2011-06-08 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド 血小板の生存を延長するための組成物および方法
ES2360215T3 (es) * 2002-12-23 2011-06-01 Albert Einstein College Of Medicine Of Yeshiva University Hemoglobinas pegiladas no hipertensivas y sus procedimientos de preparación.
AU2005279780B2 (en) 2004-08-31 2011-02-03 Sangart, Inc. Methods to enhance hemodynamic stability using oxygen carrying compositions
AU2006220548B2 (en) * 2005-03-07 2011-04-21 Sangart, Inc. Composition and methods for delivering carbon monoxide (CO) and nitric ozide (NO) CO to tissue using heme proteins as carriers
JP4665791B2 (ja) 2005-04-15 2011-04-06 ニプロ株式会社 酸素運搬体の脱一酸化炭素化方法、脱一酸化炭素化された酸素運搬体、その医薬組成物及び脱一酸化炭素化装置
US8741832B2 (en) 2005-06-10 2014-06-03 Albert Einstein College Of Medicine Of Yeshiva University Pegylated albumin and uses thereof
JP5020525B2 (ja) 2006-03-30 2012-09-05 財団法人生産開発科学研究所 配位子置換型輸液製剤
US7759306B2 (en) 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
JP2008195656A (ja) * 2007-02-14 2008-08-28 Nipro Corp 人工酸素運搬体製剤
KR102170375B1 (ko) 2009-06-09 2020-10-27 프로롱 파마슈티컬스, 엘엘씨 헤모글로빈 조성물
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
CA2764872C (en) 2018-07-24
AU2017201272A1 (en) 2017-03-16
PT2440239T (pt) 2017-10-19
EP3266463B1 (en) 2023-12-13
JP2018021032A (ja) 2018-02-08
PL3266463T3 (pl) 2024-03-18
JP6227870B2 (ja) 2017-11-08
CY1119578T1 (el) 2018-03-07
DK3266463T3 (da) 2024-01-08
RU2011153748A (ru) 2013-07-20
AU2010258752A1 (en) 2012-01-12
TWI626057B (zh) 2018-06-11
RU2589254C2 (ru) 2016-07-10
US10080782B2 (en) 2018-09-25
LT2440239T (lt) 2017-12-11
AU2018204708A1 (en) 2018-07-19
EP2440239B1 (en) 2017-09-13
KR102210133B1 (ko) 2021-02-01
IL216404A (en) 2016-06-30
NZ597022A (en) 2014-05-30
MX342787B (es) 2016-10-12
MY192541A (en) 2022-08-26
AR077041A1 (es) 2011-07-27
CL2011003091A1 (es) 2012-04-27
RS56496B1 (sr) 2018-01-31
HK1243628A1 (en) 2018-07-20
US20100311657A1 (en) 2010-12-09
EP2440239A1 (en) 2012-04-18
SMT201700546T1 (it) 2018-01-11
HRP20171480T1 (hr) 2018-01-12
TW201109034A (en) 2011-03-16
IL216404A0 (en) 2012-01-31
AU2017201272B2 (en) 2018-07-26
HUE037163T2 (hu) 2018-08-28
ZA201109176B (en) 2013-02-27
AU2010258752B2 (en) 2015-07-09
CA2764872A1 (en) 2010-12-16
KR20120052221A (ko) 2012-05-23
US10772937B2 (en) 2020-09-15
SI2440239T1 (en) 2018-01-31
AU2015238812B2 (en) 2017-04-06
ES2966234T3 (es) 2024-04-18
ES2643462T3 (es) 2017-11-23
WO2010144629A1 (en) 2010-12-16
US20190000929A1 (en) 2019-01-03
US20170072023A1 (en) 2017-03-16
BRPI1010775A2 (pt) 2016-03-22
KR20170097241A (ko) 2017-08-25
KR20190000939A (ko) 2019-01-03
MY184447A (en) 2021-04-01
JP2012529531A (ja) 2012-11-22
MX2011013215A (es) 2012-09-12
JP2016074710A (ja) 2016-05-12
JP6483766B2 (ja) 2019-03-13
AU2018204708B2 (en) 2019-07-25
AU2015238812A1 (en) 2015-10-29
CN102458451A (zh) 2012-05-16
CN102458451B (zh) 2016-10-05
ME02979B (me) 2018-10-20
KR102170375B1 (ko) 2020-10-27
EP3266463A1 (en) 2018-01-10
NO2440239T3 (da) 2018-02-10
MY199187A (en) 2023-10-19
US10780148B2 (en) 2020-09-22
KR20180126103A (ko) 2018-11-26
JP6377036B2 (ja) 2018-08-22
PL2440239T3 (pl) 2018-01-31

Similar Documents

Publication Publication Date Title
US10772937B2 (en) Hemoglobin compositions
US10172950B2 (en) Hemoglobin compositions
US10172949B2 (en) Hemoglobin compositions
WO2016022554A1 (en) Hemoglobin compositions
HK1243628B (en) Hemoglobin compositions
HK1165302B (en) Hemoglobin compositions
HK1165302A (en) Hemoglobin compositions
WO2014205077A1 (en) Hemoglobin compositions